Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Cipla , India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...

Cipla reported a 30% increase in net profit, reaching Rs 1,222 crore in Q4 FY25, fueled by higher sales in India, the US, and ...

Cipla on May 13 reported a 30 percent on-year jump in net profit to Rs 1,222 crore for the fourth quarter of the financial ...

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

The board has fixed June 27 as the record date for the purpose of payment of final dividend, as per an exchange filing.

Analysts eye margin resilience amid regulatory scrutiny; contributions likely to be seen from its US respiratory portfolio, ...

Cipla has reported 30.1% increase in consolidated net profit to Rs 1,222 crore on a 9.2% rise in total income to Rs 6,730 crore in Q4 FY25 as compared with Q4 FY24.